Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business. The company develops ALTO-100 for the treatment of patients with major depressive disorder (MDD) and post-traumatic stress disorder; ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties to treat patients with MDD; and ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor for the treatment of cognitive impairment associated with schizophrenia. It also develops ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist to treat patients with MDD and higher levels of anhedonia, and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor for the treatment of MDD. In addition, the company develops novel pharmacodynamically synergistic combinations and an AI-enabled biomarker platform that combine sources of information on patients brain activity and behavior to identify patients to respond to novel product candidates. Alto Neuroscience, Inc. was incorporated in 2019 and is based in Los Altos, California.

Alto Neuroscience, Inc.

Alto Neuroscience is redefining psychiatry by leveraging individuals' neurobiology to develop personalized and highly effective medicines, helping patients get better faster. ​

Alto's Precision Psychiatry Platform™ measures biomarkers like EEG and wearable data, behavioral patterns, genetics, and other factors to match patients with the treatment they are most likely to respond to. Our approach matches the right patient with the right Alto drug based on AI-derived brain biomarkers, redefining psychiatry at a time when the world needs it most.

K2 HealthVentures

Tim Kendall

Risk and Return

What If Ventures

Windham Venture Partners

Able Partners

Apeiron Investment Group

Presight Capital

Korify Capital

Stanford University

NJF Capital

Gaingels

Alkeon Capital

Novartis Pharma

Lightswitch Capital

Sobrato Capital

Valor Equity Partners

Vine Ventures

Alpha Wave Ventures

Bioverge

InVivium Capital

Alexandria Venture Investments

Point72 Ventures

Eli Lilly

Franklin Templeton

Alto Neuroscience

To kick off this year’s #MeetTheTeam features, we’re showcasing Khanh Tang, Alto’s Associate Director of Clinical Operations. Khanh’s role is essential in reviewing data and metrics to support the oversight of current projects, as well as planning upcoming studies. When she’s not in the office, Khanh enjoys experiencing new places, cultures, and languages.


Our product candidates in development target core #brain processes, including:

🧠 Cognition
🙂 Emotion and its regulation
💤 Sleep and circadian rhythms

Learn more: https://brnw.ch/21wGjy5

#DYK that our clinical-stage pipeline includes novel drug candidates in #Depression, #PTSD, #Schizophrenia, and other #MentalHealth conditions? Learn more about our pipeline and target indications: https://brnw.ch/21wG7u9


#Psychiatry is an ever-changing field, and treatment options will continue to evolve in 2024. At Alto, we are passionate about developments in the #MentalHealth treatment landscape and furthering our mission to bring personalized, effective treatments to people in need.


Happy holidays from the Alto Team! We're planning to spend this holiday season prioritizing our mental health and spending some time with family and loved ones.


	Dec '21	Dec '22	Dec '23
net income	-9.19M -	-27.71M 201.62%	-36.30M 31.02%
depreciation and amortization	145K -	342K 135.86%	373K 9.06%
deferred income tax
stock based compensation	227K -	1.76M 676.65%	2.89M 63.98%
change in working capital	-572K -	4.58M 900.52%	-698K 115.24%
accounts receivables	-1.28M -	1.16M 190.12%	325K 71.93%
inventory
accounts payables	458K -	1.01M 119.65%	-632K 162.82%
other working capital	255K -	2.42M 847.06%	-391K 116.19%
other non cash items	1.47M -	915K 37.71%	4.24M 362.84%
net cash provided by operating activities	-9.26M -	-20.39M 120.19%	-33.45M 64.01%
investments in property plant and equipment	-680K -	-732K 7.65%	-470K 35.79%
acquisitions net
purchases of investments
sales maturities of investments
other investing activites
net cash used for investing activites	-680K -	-732K 7.65%	-470K 35.79%
debt repayment		-9.67M -
common stock issued	31.69M -	34.12M 7.66%	69.52M 103.79%
common stock repurchased
dividends paid
other financing activites	-205K -	-341K 66.34%	-1.39M 308.50%
net cash used provided by financing activities	31.69M -	43.79M 38.19%	68.13M 55.59%
effect of forex changes on cash	-50K -	-24K 52%	-8K 66.67%
net change in cash	21.70M -	22.64M 4.35%	34.20M 51.08%
cash at beginning of period	4.01M -	25.70M 541.18%	48.34M 88.07%
cash at end of period	25.70M -	48.34M 88.07%	82.55M 70.75%
operating cash flow	-9.26M -	-20.39M 120.19%	-33.45M 64.01%
capital expenditure	-680K -	-732K 7.65%	-470K 35.79%
free cash flow	-9.94M -	-21.13M 112.49%	-33.92M 60.55%

ANRO

COM:ALTONEUROSCIENCE

Alto Neuroscience

Last Close

4.09

22/11 21:00

Market Cap

338.20M

Beta: -

Volume Today

362.06K

Avg: -

Preview